Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease

Table 1 Patient characteristics

Age (yr): median (range)	25 (19-44)
Disease duration, years median (range)	5.1 (0.4-27)
	No. of patients	%
Disease location
Ileum	2	13
Colon	4	27
Ileocolon	9	60
Disease type
Inflammatory	7	47
Stricturing	5	33
Inflammatory + perianal	3	20
Prior anti-TNF-therapy	4	27
Prior bowel operation	4	27
Smokers	7	47
Baseline concomitant medication
Azathioprine/6-mercaptopurine	10	67
Methotrexate	2	13
Corticosteroids	10	67
Mesalamine or sulphasalazine	13	87
Week 12 concomitant medication
Azathioprine/6-mercaptopurine	13	87
Methotrexate	2	13
Corticosteroids	1	6.7
Mesalamine or sulphasalazine	11	73
CDAI at baseline, median (range)	158 (49-605)
CDAI at week 12, median (range)	66 (24-202)

CDAI: Crohn’s disease activity index; TNF: Tumor necrosis factor.